BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 9581866)

  • 21. Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R).
    Ling MT; Wang X; Lee DT; Tam PC; Tsao SW; Wong YC
    Carcinogenesis; 2004 Apr; 25(4):517-25. PubMed ID: 14688027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
    Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
    Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
    Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
    Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
    Siu SW; Lau KW; Tam PC; Shiu SY
    Prostate; 2002 Jul; 52(2):106-22. PubMed ID: 12111702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model.
    Cheng L; Zhang S; Sweeney CJ; Kao C; Gardner TA; Eble JN
    Anticancer Res; 2004; 24(4):2135-40. PubMed ID: 15330153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.
    Liu CM; Lo YC; Tai MH; Wu BN; Wu WJ; Chou YH; Chai CY; Huang CH; Chen IJ
    Prostate; 2009 May; 69(6):610-23. PubMed ID: 19143029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model.
    Miyake H; Hara S; Arakawa S; Kamidono S; Hara I
    Br J Cancer; 2001 Mar; 84(6):859-63. PubMed ID: 11259104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
    Latham JP; Searle PF; Mautner V; James ND
    Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
    Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts.
    Gleave M; Hsieh JT; Gao CA; von Eschenbach AC; Chung LW
    Cancer Res; 1991 Jul; 51(14):3753-61. PubMed ID: 1712249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor.
    Eder IE; Hoffmann J; Rogatsch H; Schäfer G; Zopf D; Bartsch G; Klocker H
    Cancer Gene Ther; 2002 Feb; 9(2):117-25. PubMed ID: 11857028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline.
    Hsieh JT; Wu HC; Gleave ME; von Eschenbach AC; Chung LW
    Cancer Res; 1993 Jun; 53(12):2852-7. PubMed ID: 7684949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T; Lin FF; Rao P; Lin MF
    Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity.
    Giménez-Bonafé P; Fedoruk MN; Whitmore TG; Akbari M; Ralph JL; Ettinger S; Gleave ME; Nelson CC
    Prostate; 2004 May; 59(3):337-49. PubMed ID: 15042610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
    Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
    Cancer Res; 2000 Feb; 60(3):741-8. PubMed ID: 10676662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rap2 regulates androgen sensitivity in human prostate cancer cells.
    Bigler D; Gioeli D; Conaway MR; Weber MJ; Theodorescu D
    Prostate; 2007 Oct; 67(14):1590-9. PubMed ID: 17918750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.
    Locke JA; Guns ES; Lubik AA; Adomat HH; Hendy SC; Wood CA; Ettinger SL; Gleave ME; Nelson CC
    Cancer Res; 2008 Aug; 68(15):6407-15. PubMed ID: 18676866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nitroxide tempo, a small molecule, induces apoptosis in prostate carcinoma cells and suppresses tumor growth in athymic mice.
    Suy S; Mitchell JB; Samuni A; Mueller S; Kasid U
    Cancer; 2005 Mar; 103(6):1302-13. PubMed ID: 15685617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Agents used for chemoprevention of prostate cancer may influence PSA secretion independently of cell growth in the LNCaP model of human prostate cancer progression.
    Peternac D; Klima I; Cecchini MG; Schwaninger R; Studer UE; Thalmann GN
    Prostate; 2008 Sep; 68(12):1307-18. PubMed ID: 18512728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
    Joseph IB; Nelson JB; Denmeade SR; Isaacs JT
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2507-11. PubMed ID: 9815654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.